Cancer Therapeutic Procedure
Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline
Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases
Merck’s KEYTRUDA Receives 30th European Approval for Gynecologic Cancers
KEYTRUDA, pembrolizumab, European Commission, gynecologic cancers, endometrial cancer, cervical cancer, cancer treatment, immunotherapy.
Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants
Aktis Oncology, Series B funding, targeted alpha radiopharmaceuticals, cancer treatment, pharmaceutical industry, investment, Lilly, BMY, MRK.
Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption
UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.
Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies
Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
ImmunityBio Trims Workforce Despite Recent FDA Approval for Anktiva
ImmunityBio, Anktiva, FDA approval, layoffs, financial challenges, bladder cancer treatment
ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges
ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy
Novartis Expands Radioligand Therapy Production with Two New US Facilities
Novartis, radioligand therapy, RLT, cancer treatment, manufacturing facilities, US expansion